iX Biopharma (SGX:42C
) has posted a lower loss attributable to shareholders of the company of $2.06 million for 1HFY2026 ended Dec 31, 2025, an improvement of 67% y-o-y from $6.25 million on back of favourable exchange rate.
Loss per share for 1HFY2026 was down to 0.23 cents, compared to 0.72 cents in 1HFY2025.
Revenue declined 14% y-o-y to $3.18 million, mainly due to a lower revenue contribution from its medicinal cannabis manufacturing services provided to third parties.
“This decline was caused mainly by delays faced by the Group’s customers in securing import clearances for raw materials, which constrained their demand for the Group’s manufacturing services,” said iX Biopharma.
Gross margin improved to 26% in 1HFY2026, up from 22% in 1HFY2025, driven by a more favourable sales mix and tighter cost management.
Total assets rose to $15.9 million as at Dec 31, 2025, due to higher cash balances as a result of recent proceeds raised from the private placement and warrant exercises.
See also: Elite UK REIT reports 5.6% y-o-y rise in DPU for FY2025
Net cash used in operating activities amounted to $1.94 million for 1HFY2026, mainly due to lower receipt of R&D incentive, partially offset by tighter cost management and improved sales mix.
“With improved liquidity, a restored net asset position and continued cost discipline, the Board believes the Group is better positioned to execute its commercialisation strategy,” said iX Biopharma.
Shares in iX Biopharma was up 0.9 cents, or 4.71% higher at 20 cents on Feb 6.
